OSI Pharmaceuticals, Inc. is an American pharmaceutical company based in
Long Island, New York with facilities in Colorado, New Jersey and the United ...
R&D. Dedicated to Significant Progress. At Astellas, our commitment to R&D is
based on the development of first-in-class and best-in-class products in our ...
May 14, 2013 ... OSI Pharmaceuticals became the home-grown beacon of Long Island, NY's
biotech scene behind the lung cancer drug erlotinib (Tarceva), ...
May 17, 2010 ... Astellas Pharma (4503.T), Japan's No. 2 drugmaker, agreed to buy U.S. biotech
OSI Pharmaceuticals OSIP.O for $4 billion in cash in a ...
About OSI Pharmaceuticals OSI Pharmaceuticals, acquired by Astellas Pharma
Inc. in 2010, is a leading biotechnology company focused on the discovery and ...
Tokyo-based Astellas Pharma is rolling out a major R&D restructuring effort,
shuttering facilities at its OSI Pharmaceuticals and Perseid Therapeutics ...
May 13, 2013 ... OSI Pharmaceuticals, once the bright hope in Long Island's struggle to build a
bioscience industry, is shuttering its remaining facility in the ...
OSI's detailed financings; Comprehensive pipeline breakdown, including
molecular targets & partnerships. 17 years of in-depth BioPharma industry
May 16, 2010 ... OSI Pharmaceuticals said on Sunday that it had agreed to sell itself to Astellas
Pharma of Japan for $4 billion in cash, after its suitor raised its ...
OSI Pharmaceuticals, LLC company profile from Hoover's – get an in-depth
analysis of OSI Pharmaceuticals, LLC business, financials, industry focus, ...